PAUL LOWE: Open Payments
NPI 1659697779 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,756 in 73 payments from 12 companies in 2025. Trend: 2023 $1,989 · 2024 $2,095 · 2025 $1,756
Food & beverage: $1,756
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $322 |
| Otsuka America Pharmaceutical, Inc. | 11 | $281 |
| Axsome Therapeutics, Inc. | 3 | $244 |
| ABBVIE INC. | 23 | $227 |
| Supernus Pharmaceuticals, Inc. | 9 | $168 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Alkermes, Inc. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $94 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Bausch Health US, LLC | 2 | $46 |
Products named: INVEGA SUSTENNA, Auvelity, VRAYLAR, REXULTI, Qelbree, SPRAVATO, ARISTADA, CAPLYTA.
Industry payments across OK — which companies pay providers there.
